Ontorpacept Biosimilar – Anti-CD47 fusion protein – Research Grade

Description of Ontorpacept Biosimilar - Anti-CD47 fusion protein - Research Grade

Introduction

Ontorpacept Biosimilar is a novel anti-CD47 fusion protein that has been gaining attention in the scientific community for its potential therapeutic applications. This biosimilar is a fusion of an antibody and a therapeutic protein, designed to target the CD47 protein. In this article, we will delve into the structure, activity, and potential applications of Ontorpacept Biosimilar as a research grade molecule.

Structure of Ontorpacept Biosimilar

Ontorpacept Biosimilar is a fusion protein consisting of two main components – an antibody and a therapeutic protein. The antibody portion of the molecule is derived from a monoclonal antibody that specifically binds to the CD47 protein. This antibody has been extensively modified to enhance its binding affinity and specificity towards CD47. The therapeutic protein component of Ontorpacept Biosimilar is a small peptide that has been engineered to have potent anti- cancer activity. This peptide is fused to the antibody through a linker sequence, resulting in a single, stable molecule.

Activity of Ontorpacept Biosimilar

The main activity of Ontorpacept Biosimilar is its ability to target and bind to the CD47 protein. CD47 is a transmembrane protein that is overexpressed in various types of cancer cells, allowing them to evade the body’s immune response and proliferate uncontrollably. By binding to CD47, Ontorpacept Biosimilar blocks its interaction with the signal regulatory protein alpha (SIRPα), which is responsible for the “don’t eat me” signal that cancer cells use to evade immune cells. This disruption of the CD47-SIRPα interaction leads to the activation of macrophages and other immune cells, which then recognize and destroy the cancer cells.

In addition to its anti-

cancer activity, Ontorpacept Biosimilar also has anti-inflammatory effects. The antibody component of the molecule has been shown to bind to the Fcγ receptors on immune cells, triggering an anti-inflammatory response. This makes Ontorpacept Biosimilar a potential therapeutic option for inflammatory diseases.

Potential Applications of Ontorpacept Biosimilar

Ontorpacept Biosimilar has shown promising results in preclinical studies as a potential treatment for various types of cancer, including leukemia, lymphoma, and solid tumors. Its ability to activate the immune system and induce cancer cell death makes it a promising candidate for combination therapies with other anti- cancer drugs.

Moreover, the anti-inflammatory effects of Ontorpacept Biosimilar make it a potential treatment for inflammatory diseases such as rheumatoid arthritis and multiple sclerosis. Its dual mechanism of action, targeting both cancer cells and inflammation, makes it a versatile molecule with potential applications in various disease conditions.

Conclusion

Ontorpacept Biosimilar is a unique fusion protein with the potential to revolutionize cancer treatment and other disease conditions. Its structure, activity, and potential applications make it a promising research grade molecule that warrants further investigation. With ongoing clinical trials, Ontorpacept Biosimilar may soon become a valuable addition to the arsenal of anti- cancer and anti-inflammatory therapies.